Seeking Alpha
Long only, growth, long-term horizon, short-term horizon
Profile| Send Message|
( followers)

Summary

  • 5 high-quality growing stocks to buy before earnings.
  • Earnings estimates.
  • Each of these stocks is set to soar during the earnings season.

The stocks in our system are evaluated by Fundamental grade, Buying pressure grade and Overall grade. Stocks are evaluated from A to E (A is best grade and E is worst grade).

So here are the 5 Strong Buy high-quality growing stocks to buy before earnings.

Stock name

Ticker

Fundamental grade

Buying pressure grade

Overall grade

Illumina

ILMN

A

B

A

Facebook

FB

A

A

A

Gilead Sciences

GILD

A

A

A

Apple

AAPL

A

A

A

Anika Therapeutics

ANIK

A

B

A

Illumina ($ILMN) - San Diego based company develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Analysts are looking for a solid quarter with earnings gains of 18% on 23% revenue growth. Analysts may be underestimating the quarter, though, as Illumina has posted four consecutive positive surprises and estimates have been rising over the past 90 days. The stock has the best overall A-Strong Buy rate as we get closer to the July 23 earnings release.

Facebook ($FB).- well known social media company books constant increasing of users in last years and that shows in excellent earnings growth and sales growth results. Still, there are plenty of us "old" folks who like using Facebook to stay in touch with family and friends. Facebook has delivered four solid positive earnings surprises in a row, and I expect another when the company reports earnings on July 23. FB analysts expect Facebook to report earnings of $0.32 a share on sales of $2.8 billion for the quarter. Our grading system gives FB the A-Strong Buy grade and it remains a high quality growth stock as we head deeper into earnings season.

Gilead Sciences ($GILD) - California based biopharmaceutical company shows truly excellent fundamental results. Earnings are expected to more than triple from last year's $0.50 a share to $1.72. Wall Street sees revenue more than doubling, with a 102% year-over-year increase in sales. Estimates have surged by almost 70% in the past three months and analysts have continued to revise expectations higher in the past few weeks. Gilead was raised to an A-Strong Buy grade back in November and is still a "strong buy" going into the July 23 earnings release. Gilead Sciences is one of the best high quality growing biotech stocks to buy before earnings.

Apple ($AAPL) - remains one of the very best tech stocks to own. Consumers love Apple's products - Apple doesn't have customers so much as devotees. Analysts continually underestimate this company; Apple has had small positive earnings surprises for the past four quarters in a row. As we get closer to the July 22 earnings release, several AAPL analysts have raised their expectations for Apple stock. Currently the consensus is for Apple to earn $1.22 a share on revenues of $37.8 billion … but I will not be surprised if Apple beats expectations once again. AAPL stock is an A-Strong Buy stock in front of earnings.

Anika Therapeutics ($ANIK) - recently had a drug approved for knee pain and joint mobility that is driving the growth for this company. Monovisc is an injectable drug that addresses a huge market. Knee osteoarthritis affects an enormous percentage of folks over the age of 50 in the United States. Analysts are expecting big things when Anika reports earnings on July 28. Earnings are expected to rise by more than 40% to $0.57 a share on 35% revenue growth. As impressive as that is, consider that Wall Street routinely underestimates ANIK; Anika has posted four consecutive earning surprises, including a triple-digit beat in the first quarter of 2014.

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.